Congenital Fibrinogen Disorders

  • Akbar Dorgalaleh
  • Alessandro CasiniEmail author
  • Parvin Rahmani


Congenital fibrinogen disorders (CFD) are rare coagulation disorders. CFD can affect quantity (afibrinogenemia and hypofibrinogenemia), quality (dysfibrinogenemia), or both aspects (hypodysfibrinogenemia) of the fibrinogen molecule. The precise prevalence of CFD is not known, except for afibrinogenemia with an estimated incidence of 1 per 1,000,000 of person. Most patients with hypofibrinogenemia and dysfibrinogenemia are asymptomatic, while hemorrhage is frequent in afibrinogenemia often with umbilical cord bleeding at diagnosis. Thrombotic and obstetrical complications are also a common complication in patients with CFD. Diagnosis is based on the assessment of both antigenic and functional fibrinogen levels. In routine clinical use, the Clauss functional assay is recommended, although a variety of functional and antigenic assays with variable sensitivity are available. Genotype helps to confirm the diagnosis. A wide spectrum of mutations has been discovered in FGA, FGB, and FGG encoding the three chains of fibrinogen molecule. Two hotspot mutations are prevalent in afibrinogenemia and dysfibrinogenemia. Management of patients with congenital fibrinogen disorders is challenging and should always take in account the personal and familial history as well as the genotype in qualitative fibrinogen disorders.


Congenital fibrinogen disorders Rare coagulation disorders Diagnosis Clinical manifestation Afibrinogenemia Hypofibrinogenemia Dysfibrinogenemia Hypodysfibrinogenemia 


  1. 1.
    Neerman-Arbez M, De Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost. 2016;42:356–65.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. 2015;125(13):2052–61.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Casini A, De Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost. 2016;42:366–74.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Dorgalaleh A, Alavi SER, Tabibian S, Soori S, Moradi EH, Bamedi T, et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology. 2017;22(4):224–30.CrossRefPubMedGoogle Scholar
  5. 5.
    De Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39:585–95.CrossRefPubMedGoogle Scholar
  6. 6.
    Menache D. Congenital fibrinogen abnormalities. Ann N Y Acad Sci. 1983;408(1):121–30.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Casini A, Neerman-Arbez M, Ariens R, Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015;13(6):909–19.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    De Moerloose P, Neerman-Arbez M. Treatment of congenital fibrinogen disorders. Expert Opin Biol Ther. 2008;8(7):979–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Molmenti EP, Ziambaras T, Perlmutter DH. Evidence for an acute phase response in human intestinal epithelial cells. J Biol Chem. 1993;268:14116–24.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Lee SY, Lee KP, Lim JW. Identification and biosynthesis of fibrinogen in human uterine cervix carcinoma cells. Thromb Haemost. 1996;75:466–70.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Simpson-Haidaris PJ. Induction of fibrinogen biosynthesis and secretion from cultured pulmonary epithelial cells. Blood. 1997;89:873–82.Google Scholar
  12. 12.
    Francis CW, Nachman RL, Marder VJ. Plasma and platelet fibrinogen differ in gamma chain content. Thromb Haemost. 1984;51(1):84–8.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Soria J, Soria C, Samama M, Poirot E, Kling C. Human platelet fibrinogen: a protein different from plasma fibrinogen. Pathol Biol. 1976;24:15–7.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Blombäck B. Fibrinogen structure, activation, polymerization and fibrin gel structure. Thromb Res. 1994;75(3):327–8.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Mosesson MW. Fibrinogen structure and fibrin clot assembly. Semin Thromb Hemost. 1998;24:169–74.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Söderqvist T, Blombäck B. Fibrinogen structure and evolution. Naturwissenschaften. 1971;58(1):16–23.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Fish RJ, Neerman-Arbez M. Fibrinogen gene regulation. Thromb Haemost. 2012;108(3):419–26.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Crabtree GR, Comeau CM, Fowlkes DM, Fornace AJ, Malley JD, Kant JA. Evolution and structure of the fibrinogen genes: random insertion of introns or selective loss? J Mol Biol. 1985;185(1):1–19.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Henry I, Uzan G, Weil D, Nicolas H, Kaplan J, Marguerie C, et al. The genes coding for A alpha-, B beta-, and gamma-chains of fibrinogen map to 4q2. Am J Hum Genet. 1984;36(4):760.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Asselta R, Duga S, Tenchini M. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost. 2006;4(10):2115–29.CrossRefPubMedGoogle Scholar
  21. 21.
    Macrae FL, Domingues MM, Casini A, Ariëns RA. The (Patho)physiology of fibrinogen γ′. Semin Thromb Hemost. 2016;42(4):344–55.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    De Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost. 2009;35:356–66.CrossRefPubMedGoogle Scholar
  23. 23.
    Neerman-Arbez M, Tirefort Y, de Moerloose P. Can mutations identified in congenital fibrinogen disorders explain the clinical manifestations. J Coagul Disord. 2010;2(2):1–9.Google Scholar
  24. 24.
    Stanciakova L, Kubisz P, Dobrotova M, Stasko J. Congenital afibrinogenemia: from etiopathogenesis to challenging clinical management. Expert Rev Hematol. 2016;9(7):639–48.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Ogata Y, Hepplmann CJ, Charlesworth MC, Madden BJ, Miller MN, Kalli KR, et al. Elevated levels of phosphorylated fibrinogen-α-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients. J Proteome Res. 2006;5(12):3318–25.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, Visser J, et al. Fibrinogen β-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem. 2008;283(49):33846–53.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Medved L, Weisel JW, Fibrinogen and Factor XIII Subcommittee of Scientific Standardization Committee of International Society on Thrombosis and Haemostasis. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost. 2009;7(2):355–9.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Mosesson M. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3(8):1894–904.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci. 1980;77(3):1374–8.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Gorkun OV, Veklich YI, Medved LV, Henschen AH, Weisel JW. Role of the alpha C domains of fibrin in clot formation. Biochemistry. 1994;33(22):6986–97.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Li X, Galanakis D, Gabriel DA. Transient intermediates in the thrombin activation of fibrinogen evidence for only the desAA species. J Biol Chem. 1996;271(20):11767–71.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev. 2016;30(6):461–75.CrossRefPubMedGoogle Scholar
  33. 33.
    Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94(5):271–305.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci. 1996;33(5):357–421.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Drew AF, Liu H, Davidson JM, Daugherty CC, Degen JL. Wound-healing defects in mice lacking fibrinogen. Blood. 2001;97(12):3691–8.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Clark RA. Fibrin and wound healing. Ann N Y Acad Sci. 2001;936(1):355–67.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Investig. 1991;87(4):1234.PubMedCrossRefGoogle Scholar
  38. 38.
    Staton CA, Brown NJ, Lewis CE. The role of fibrinogen and related fragments in tumour angiogenesis and metastasis. Expert Opin Biol Ther. 2003;3(7):1105–20.PubMedCrossRefGoogle Scholar
  39. 39.
    Rybarczyk BJ, Lawrence SO, Simpson-Haidaris PJ. Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration. Blood. 2003;102(12):4035–43.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Suh TT, Holmbäck K, Jensen NJ, Daugherty CC, Small K, Simon DI, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995;9(16):2020–33.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell. 1989;58(5):945–53.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res. 2012;130:S7–S11.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    El Boussaadni Y, Benajiba N, El Ouali A, Amrani R, Rkain M. Congenital afibrinogenemia: a case report. Archives de pediatrie: organe officiel de la Societe francaise de. Pediatrie. 2015;22(1):50–2.Google Scholar
  44. 44.
    Peyvandi F, Palla R, Menegatti M, Siboni S, Halimeh S, Faeser B, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615–21.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Peyvandi F, Di Michele D, Bolton-Maggs P, Lee C, Tripodi A, Srivastava A. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost. 2012;10(9):1938–43.CrossRefPubMedGoogle Scholar
  46. 46.
    Lebreton A, Casini A. Diagnosis of congenital fibrinogen disorders. Ann Biol Clin. 2016;74:405–12.Google Scholar
  47. 47.
    Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med. 2002;126(4):499–505.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res. 2010;126(6):e428–e33.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Al-Mondhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol. 1994;46(4):343–7.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Henselmans J, Meijer K, Haaxma R, Hew J, van Der Meer J. Recurrent spontaneous intracerebral hemorrhage in a congenitally afibrinogenemic patient. Stroke. 1999;30(11):2479–82.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Taslimi R, Golshani K. Thrombotic and hemorrhagic presentation of congenital hypo/afibrinogenemia. Am J Emerg Med. 2011;29(5):573.e3–5.CrossRefGoogle Scholar
  52. 52.
    Paolini R, Sartori MT, Fiorin F, Gorinati M, Boeri G, Girolami A. Perinatal intracranial hemorrhage as first manifestation of congenital hypofibrinogenemia. Clin Appl Thromb Hemost. 1996;2(1):60–3.CrossRefGoogle Scholar
  53. 53.
    Fettah A, Gökçebay DG, Çulha V, Yaralı N, Tunç B, Özbek N. A rare complication of congenital afibrinogenemia: bone cysts. Turk J Haematol. 2017;34(2):183.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Ehmann WC, Al-Mondhiry H. Congenital afibrinogenemia and splenic rupture. Am J Med. 1994;96(1):92–4.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol. 2016;95(3):451–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Trehan A, Fergusson I. Congenital afibrinogenaemia and successful pregnancy outcome. Case report. Br J Obstet Gynaecol. 1991;98(7):722–4.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Zdziarska J, Undas A, Basa J, Iwaniec T, Skotnicki AB, De Moerloose P, et al. Severe bleeding and miscarriages in a hypofibrinogenemic woman heterozygous for the γAla82Gly mutation. Blood Coagul Fibrinolysis. 2009;20(5):374–6.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Santoro C, Massaro F, Venosi S, Capria S, Baldacci E, Foà R, Mazzucconi MG. Severe thrombotic complications in congenital afibrinogenemia: a pathophysiological and management dilemma. Semin Thromb Hemost. 2016;42(5):577–82.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Rottenstreich A, Lask A, Schliamser L, Zivelin A, Seligsohn U, Kalish Y. Thromboembolic events in patients with severe inherited fibrinogen deficiency. J Thromb Thrombolysis. 2016;42(2):261–6.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Sartori MT, Milan M, de Bon E, Fadin M, Pesavento R, Zanon E. Thrombosis of abdominal aorta in congenital afibrinogenemia: case report and review of literature. Haemophilia. 2015;21(1):88–94.PubMedCrossRefGoogle Scholar
  61. 61.
    Frenkel E, Duksin C, Herman A, Sherman DJ. Congenital hypofibrinogenemia in pregnancy: report of two cases and review of the literature. Obstet Gynecol Surv. 2004;59(11):775–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Awasthy N, Aggarwal K, Gupta H, Saluja S. Congenital hypofibrinogenemia. Indian Pediatr. 2004;41(2):185–6.PubMedGoogle Scholar
  63. 63.
    Hasselback R, Marion RB, Thomas J. Congenital hypofibrinogenemia in five members of a family. Can Med Assoc J. 1963;88(1):19.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Bay A, Coskun E, Leblebisatan G, Sivasli E. Epidural hematoma and cephalohematoma with congenital hypofibrinogenemia. Blood Coagul Fibrinolysis. 2012;23(3):229–31.PubMedCrossRefGoogle Scholar
  65. 65.
    Rubbia-Brandt L, Neerman-Arbez M, Rougemont A-L, Malé P-J, Spahr L. Fibrinogen gamma375 arg→ trp mutation (fibrinogen aguadilla) causes hereditary hypofibrinogenemia, hepatic endoplasmic reticulum storage disease and cirrhosis. Am J Surg Pathol. 2006;30(7):906–11.PubMedCrossRefGoogle Scholar
  66. 66.
    Wehinger H, Klinge O, Alexandrakis E, Schürmann J, Witt J, Seydewitz H. Hereditary hypofibrinogenemia with fibrinogen storage in the liver. Eur J Pediatr. 1983;141(2):109–12.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Pfeifer U, Ormanns W, Klinge O. Hepatocellular fibrinogen storage in familial hypofibrinogenemia. Virchows Arch B. 1981;36(1):247–55.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Casini A, Sokollik C, Lukowski S, Lurz E, Rieubland C, Moerloose P, et al. Hypofibrinogenemia and liver disease: a new case of Aguadilla fibrinogen and review of the literature. Haemophilia. 2015;21(6):820–7.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Asselta R, Robusto M, Braidotti P, Peyvandi F, Nastasio S, D’antiga L, et al. Hepatic fibrinogen storage disease: identification of two novel mutations (p. Asp316Asn, fibrinogen Pisa and p. Gly366Ser, fibrinogen Beograd) impacting on the fibrinogen γ-module. J Thromb Haemost. 2015;13(8):1459–67.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Puls F, Goldschmidt I, Bantel H, Agne C, Bröcker V, Dämmrich M, et al. Autophagy-enhancing drug carbamazepine diminishes hepatocellular death in fibrinogen storage disease. J Hepatol. 2013;59(3):626–30.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Casini A, Duval C, Pan X, Tintillier V, Biron-Andreani C, Ariëns R. Fibrin clot structure in patients with congenital dysfibrinogenaemia. Thromb Res. 2016;137:189–95.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E, et al. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125(3):553–61.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Miesbach W, Galanakis D, Scharrer I. Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. Blood Coagul Fibrinolysis. 2009;20(5):366–70.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Miesbach W, Scharrer I, Henschen A, Neerman-Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis. 2010;21(1):35–40.PubMedCrossRefGoogle Scholar
  75. 75.
    Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med. 2002;126(11):1387–90.PubMedGoogle Scholar
  76. 76.
    Rowczenio D, Stensland M, de Souza GA, Strøm EH, Gilbertson JA, Taylor G, et al. Renal amyloidosis associated with five novel variants in the fibrinogen A alpha chain protein. Kidney Int Rep. 2017;2:461–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Casini A, Brungs T, Lavenu-Bombled C, Vilar R, Neerman-Arbez M, Moerloose P. Genetics, diagnosis and clinical features of congenital hypodysfibrinogenemia: a systematic literature review and report of a novel mutation. J Thromb Haemost. 2017;15(5):876–88.PubMedCrossRefGoogle Scholar
  78. 78.
    Deering SH, Landy HJ, Tchabo N, Kessler C. Hypodysfibrinogenemia during pregnancy, labor, and delivery. Obstet Gynecol. 2003;101(5, Part 2):1092–4.PubMedCrossRefGoogle Scholar
  79. 79.
    Cheah CY, Brennan SO, Kennedy H, Januszewicz EH, Maxwell E, Burbury K. Fibrinogen Melbourne: a novel congenital hypodysfibrinogenemia caused by γ326Cys-Phe in the fibrinogen γ chain, presenting as massive splanchnic venous thrombosis. Blood Coagul Fibrinolysis. 2012;23(6):563–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Ebert RF, Bell WR. Fibrinogen Baltimore II: congenital hypodysfibrinogenemia with delayed release of fibrinopeptide B and decreased rate of fibrinogen synthesis. Proc Natl Acad Sci. 1983;80(23):7318–22.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Lefebvre P, Velasco PT, Dear A, Lounes KC, Lord ST, Brennan SO, et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AαIVS4+ 1G> T mutation and an AαGln328 truncation (fibrinogen Keokuk). Blood. 2004;103(7):2571–6.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Jayo A, Arnold E, González-Manchón C, Green D, Lord ST. Hypodysfibrinogenemia causing mild bleeding and thrombotic complications in a compound heterozygote of AαIVS4+ 1G> T mutation and Aα4841delC truncation (AαPerth). Thromb Haemost. 2009;101(4):770.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Duga S, Asselta R, Santagostino E, Zeinali S, Simonic T, Malcovati M, et al. Missense mutations in the human β fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Blood. 2000;95(4):1336–41.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Neerman-Arbez M, De Moerloose P, Bridel C, Honsberger A, Schönbörner A, Rossier C, et al. Mutations in the fibrinogen Aα gene account for the majority of cases of congenital afibrinogenemia. Blood. 2000;96(1):149–52.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Neerman-Arbez M. The molecular basis of inherited afibrinogenaemia. Thromb Haemost. 2001;86(1):154–63.PubMedGoogle Scholar
  86. 86.
    Uzan G, Courtois G, Besmond C, Frain M, Sala-Trepat J, Kahn A, et al. Analysis of fibrinogen genes in patients with congenital afibrinogenemia. Biochem Biophys Res Commun. 1984;120(2):376–83.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Neerman-Arbez M, De Moerloose P. Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations. Hum Mutat. 2007;28(6):540.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Brennan SO, Fellowes AP, George PM. Molecular mechanisms of hypo-and afibrinogenemia. Ann N Y Acad Sci. 2001;936(1):91–100.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Neerman-Arbez M, De Moerloose P, Honsberger A, Parlier G, Arnuti B, Biron C, et al. Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes. Hum Genet. 2001;108(3):237–40.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Neerman-Arbez M, Vu D, Abu-Libdeh B, Bouchardy I, Morris MA. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family. Blood. 2003;101(9):3492–4.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Asselta R, Spena S, Duga S, Peyvandi F, Malcovati M, Mannucci PM, et al. Analysis of Iranian patients allowed the identification of the first truncating mutation in the fibrinogen Bbeta-chain gene causing afibrinogenemia. Haematologica. 2002;87(8):855–9.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Brennan SO, Davis RL, Conard K, Savo A, Furuya KN. Novel fibrinogen mutation γ314Thr→ Pro (fibrinogen AI duPont) associated with hepatic fibrinogen storage disease and hypofibrinogenaemia. Liver Int. 2010;30(10):1541–7.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Lee MJ, Venick R, Bhuta S, Li X, Wang HL. Hepatic fibrinogen storage disease in a patient with hypofibrinogenemia: report of a case with a missense mutation of the FGA gene. Semin Liver Dis. 2015;35:439–43.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Asselta R, Platè M, Robusto M, Borhany M, Guella I, Soldà G, et al. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thromb Haemost. 2015;113(3):567–76.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Sumitha E, Jayandharan G, Arora N, Abraham A, David S, Devi G, et al. Molecular basis of quantitative fibrinogen disorders in 27 patients from India. Haemophilia. 2013;19(4):611–8.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord S. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA--> stop TAA). Blood. 1992;80(8):1972–9.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost. 2007;5(s1):125–31.CrossRefPubMedGoogle Scholar
  98. 98.
    Zhou J, Ding Q, Chen Y, Ouyang Q, Jiang L, Dai J, et al. Clinical features and molecular basis of 102 Chinese patients with congenital dysfibrinogenemia. Blood Cell Mol Dis. 2015;55(4):308–15.CrossRefGoogle Scholar
  99. 99.
    Hill M, Dolan G. Diagnosis, clinical features and molecular assessment of the dysfibrinogenaemias. Haemophilia. 2008;14(5):889–97.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Verhovsek M, Moffat KA, Hayward CP. Laboratory testing for fibrinogen abnormalities. Am J Hematol. 2008;83(12):928–31.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Sadeghian MH, Keramati MR, Badiei Z, Ravarian M, Ayatollahi H, Rafatpanah H, et al. Alloimmunization among transfusion-dependent thalassemia patients. Asian J Transfus Sci. 2009;3(2):95.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Ridgway HJ, Brennan SO, Faed JM, George PM. Fibrinogen Otago: a major α chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol. 1997;98(3):632–9.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Martinez J, Holburn R, Shapiro S, Erslev A. Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism. J Clin Investig. 1974;53(2):600.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Mukai S, Nagata K, Ikeda M, Arai S, Sugano M, Honda T, et al. Genetic analyses of novel compound heterozygous hypodysfibrinogenemia, Tsukuba I: FGG c. 1129+ 62_65 del AATA and FGG c. 1299+ 4 del A. Thromb Res. 2016;148:111–7.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Harr JN, Moore EE, Ghasabyan A, Chin TL, Sauaia A, Banerjee A, et al. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock. 2013;39(1):45.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Mackie I, Lawrie A, Kitchen S, Gaffney P, Howarth D, Lowe G, et al. A performance evaluation of commercial fibrinogen reference preparations and assays for Clauss and PT-derived fibrinogen. Thromb Haemost. 2002;87(6):997–1005.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Mackie IJ, Kitchen S, Machin SJ, Lowe G. Guidelines on fibrinogen assays. Br J Haematol. 2003;121(3):396–404.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Exner T, Burridge J, Power P, Rickard KA. An evaluation of currently available methods for plasma fibrinogen. Am J Clin Pathol. 1979;71(5):521–7.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Desvignes P, Bonnet P. Direct determination of plasma fibrinogen levels by heat precipitation. A comparison of the technique against thrombin clottable fibrinogen with spectrophotometry and radial immuno-diffusion. Clin Chim Acta. 1981;110(1):9–17.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Besser MW, MacDonald SG. Acquired hypofibrinogenemia: current perspectives. J Blood Med. 2016;7:217.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Casini A, de Moerloose P. Can the phenotype of inherited fibrinogen disorders be predicted? Haemophilia. 2016;22(5):667–75.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol. 2013;160(2):220–7.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Godal H, Brosstad F, Kierulf P. Three new cases of an inborn qualitative fibrinogen defect (Fibrinogen Oslo II). Eur J Haematol. 1978;20(1):57–62.Google Scholar
  114. 114.
    Acharya S, Coughlin A, Dimichele DM. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost. 2004;2(2):248–56.CrossRefPubMedGoogle Scholar
  115. 115.
    Casini A, de Moerloose P, Congenital Fibrinogen Disorders Group. Management of congenital quantitative fibrinogen disorders: a Delphi consensus. Haemophilia. 2016;22(6):898–905.PubMedCrossRefGoogle Scholar
  116. 116.
    Mumford AD, Ackroyd S, Alikhan R, Bowles L, Chowdary P, Grainger J, et al. Guideline for the diagnosis and management of the rare coagulation disorders. Br J Haematol. 2014;167(3):304–26.CrossRefPubMedGoogle Scholar
  117. 117.
    Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, Collins PW, Kitchen S, Dolan G, Mumford AD. The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia. 2004;10(5):593–628.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Akbar Dorgalaleh
    • 1
  • Alessandro Casini
    • 2
    Email author
  • Parvin Rahmani
    • 3
  1. 1.Department of Hematology and Blood Transfusion, School of Allied MedicineIran University of Medical SciencesTehranIran
  2. 2.Division of Angiology and Haemostasis, Faculty of MedicineUniversity Hospitals of GenevaGenevaSwitzerland
  3. 3.Department of Hematology and Blood Transfusion, School of Allied MedicineTehran University of Medical SciencesTehranIran

Personalised recommendations